Korea Research Institute of Chemical Technology has identified glutaminase inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Researchers at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of inflammatory disorders.
Scientists at Arontier Co. Ltd. and Korea Research Institute of Chemical Technology have disclosed ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of hepatic steatosis, hepatic fibrosis, cirrhosis, liver failure, hepatitis and liver cancer, among others.
Scientists at University of Connecticut and University of Iowa have described phosphonamidate prodrugs reported to be useful for the treatment of cancer.
Jiangsu Simcere Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker reported to be useful for the treatment of cancer, neurodegeneration, infections, autoimmune and inflammatory disorders.
Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.
Yuhan Corp. has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Shanghai Yiweikang Pharmaceutical Co. Ltd. has divulged camptothecin derivatives acting as DNA topoisomerase I inhibitors reported to be useful for the treatment of cancer.
RSS